To all,

Take a look at the fundamentals between RVX and CP.  RVX, 209 M + shares outstanding with no cash in post Phase 3, has payables, no abliltiy to produce income, but no negative side effects. Constellation Pharma, 41 M shares + with 359M in cash, marketable securities and little payables.  RVX was there once, Phase 2a&b came and Phase 3 happened.  CP has many years head (only in Phase 2) and as Bear pointed, CP is not in competition with RVX. CP’s 359M will disappear and if any events occur that does not meet end point, gone baby gone.  Look back to 2003, believe RVX was $20+ (maybe 30C) per share with 40 + M shares.  Now you know why CP has value of 1.2B (all hope and hype).  CP in June had one or two announcements per day, great marketing.  They will keep selling shares too.  Look at their income statement, no income, just expenses.  Sound familiar?  It is very expensive to bring an idea in medication to full FDA approval, my guess, one idea will make the grade out of 10,000 with average of 14 years in research and costing near 600 to 700 M in today’s market.

Still believe, IR responded to COVID question, answer, Apabetalone IS being used in test for COVID 19 (yes, one of thousands).  We know Apabetalone is ACE2 inhibitor and has many anti-inflammatory properties.  The corona virus is very complex and there are many different responses by our immune system.  There are no answers now, just many questions.  We will see.